A Phase II Trial of Early Intervention With Acalabrutinib in Patients With CLL at High Risk for Richter's Transformation
Latest Information Update: 11 Apr 2022
At a glance
- Drugs Acalabrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 25 Mar 2022 Planned initiation date changed from 1 Feb 2022 to 1 May 2022.
- 25 Mar 2022 Status changed from not yet recruiting to withdrawn prior to enrolment. Reason the study was stopped: Company supplying drug/funding ceased support.
- 20 Nov 2021 Planned initiation date changed from 1 Sep 2021 to 1 Feb 2022.